Tripos Announces Chemistry Collaboration with Abbott
News Mar 21, 2006
Tripos, Inc. has announced a chemistry collaboration with Abbott to design, synthesize and purify high-quality, novel, drug-like compounds to expand Abbott’s compound file collection. Tripos and Abbott will collaborate in library design, analysis and synthesis.
"The success of high-throughput technologies in pharmaceutical research is highly dependent on the close coupling of informatics and experimental science," said Dr. John P. McAlister, president and chief executive officer of Tripos.
"With its fully integrated, information-driven chemistry operations, including cutting-edge ChemCore™ and ChemSpace® technologies, Tripos is positioned to add value to the chemical libraries delivered to Abbott."
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE